13 Jun 2017 07:00
Byotrol Plc
("Byotrol" or the "Company")
APPROVAL RECEIVED FROM U.S. ENVIRONMENTAL PROTECTION AGENCY ("EPA")
FOR LONG-LASTING ANTI-MICROBIAL PRODUCT
Byotrol plc, the specialist anti-microbial technology company, is pleased to announce that the US EPA has formally approved Byotrol's proprietary 24-hour germ-kill surface sanitizer for sale in the US (EPA Reg. Number 83614-1).
The formulation has been under development at Byotrol for over seven years and the Directors believe offers unique performance characteristics to US consumers and businesses.
To US consumers our products will be able to claim high performance cleaning and viricidal action, plus long-lasting benefits such as:
· 24-hour surface protection against bacteria
· Scientifically proven to kill >99.9% of bacteria for 24 hours
· 7 day mold and mildew prevention
· Eliminates >99.9% of viruses
The Directors are not aware of any other cleaning or sanitizing products that can make such claims for US consumers; we believe this approval gives Byotrol a unique opportunity in the substantial US market.
To US businesses, the formulation will be positioned to offer cost-benefits, such as higher infection control for less chemical use and decreased absenteeism from work.
The EPA has specifically approved the product's use (and the 24-hour claim) in domestic households, travel and leisure, janitorial and sanitation environments, pet and vet environments and all non-food contact surfaces. The product has also been approved for use as a surface sanitizer in hospital environments.
The Company has been exploring alliances and commercial opportunities with various US organisations since the application was made to the EPA. Today's approval allows us to accelerate these discussions.
David Traynor, Chief Executive of Byotrol plc comments:
"We are very excited to gain this registration. This project is one of 3 core R&D initiatives in the Company, so its successful conclusion is a very significant moment for us.
We are not aware of any product in the US market that can make competing 24-hour germ-kill claims, yet we are very confident that such claims are valued by both consumers and business users in markets that we estimate in retail alone total over US$1bn."
Enquiries:
Byotrol plc 01925 742 000
David Traynor - Chief Executive
finnCap Ltd 020 7220 0500(Nominated Adviser & Broker)
Geoff Nash/Carl Holmes/James Thompson - Corporate Finance
The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.
Notes to Editors:
Byotrol plc (BYOT.L), quoted on AIM, is a specialist developer of residual antimicrobial technologies, identifying, developing, formulating and commercialising cutting-edge antimicrobial solutions.
Our patented suite of technologies deliver powerful broad-spectrum efficacy with residual performance optimised against commonly occurring and industry-specific pathogens
Founded in 2005, the Company has developed the technology that creates easier, safer and cleaner lives
For more information, please go to www.byotrol.co.uk